The Gastrointestinal Complications of Oncologic Therapy

Gastroenterology Clinics of North America

Volumn 39, Issue 3, 2010, Pages 629-647

  Shafi, Mehnaz A ^a   Bresalier, Robert S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Chemotherapy induced nausea and vomiting; Drug induced diarrhea; Graft versus host disease; Liver injury; Neutropenic enterocolitis

Indexed keywords

ACICLOVIR; AMPHOTERICIN B DEOXYCHOLATE; BECLOMETASONE; BEVACIZUMAB; CAPECITABINE; CLOTRIMAZOLE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ECHINOCANDIN; FLUCONAZOLE; FLUOROURACIL; FOLINIC ACID; FOSCARNET SODIUM; GANCICLOVIR; IRINOTECAN; LAMIVUDINE; LOPERAMIDE; METHYLPREDNISOLONE; METRONIDAZOLE; MICAFUNGIN; MICONAZOLE; OCTREOTIDE; PREDNISONE; THALIDOMIDE; UNINDEXED DRUG; VANCOMYCIN; VINCRISTINE; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE PANCREATITIS; ARTERY THROMBOSIS; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL DEATH; CHRONIC GRAFT VERSUS HOST DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG RESPONSE; ENZYME INHIBITION; ESOPHAGITIS; ESOPHAGUS CANDIDIASIS; EXTERNAL BEAM RADIOTHERAPY; FATTY LIVER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GRAFT VERSUS HOST REACTION; HEPATITIS; HEPATITIS B; HUMAN; IMMUNOCOMPROMISED PATIENT; LIVER CELL DAMAGE; LIVER TOXICITY; MALIGNANT NEOPLASTIC DISEASE; MYCOSIS; NAUSEA AND VOMITING; NEUTROPENIC ENTEROCOLITIS; OROPHARYNX CANDIDIASIS; PROCTITIS; RECOMMENDED DRUG DOSE; REVIEW; STEM CELL TRANSPLANTATION; STOMATITIS; VIRUS INFECTION;

ANTINEOPLASTIC AGENTS; CONSTIPATION; DIARRHEA; ENTEROCOLITIS, NEUTROPENIC; ESOPHAGITIS; GRAFT VS HOST DISEASE; HEPATITIS; HUMANS; NAUSEA; NEOPLASMS; PROCTITIS; RADIOTHERAPY; VOMITING;

EID: 77957905259     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2010.08.004     Document Type: Review

References (81)

1. Benson C.A., Kaplan J.E., Masur H., et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep 2004, 53(RR-15):1-112.
2. Choy H., LaPorte K., Knill-Selby E., et al. Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semin Radiat Oncol 1999, 9(2 Suppl 1):90-96.
3. McDonald G.B., Sharma P., Hackman R.C., et al. Esophageal infections in immunosuppressed patients after marrow transplantation. Gastroenterology 1985, 88(5 Pt 1):1111-1117.
4. Pappas P.G., Kauffman C.A., Andes D., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48(5):503-535.
5. Kaplan J.E., Benson C., Holmes K.H., et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009, 58(RR-4):1-207. quiz CE201-4.
6. Hegener P., Troke P.F., Fatkenheuer G., et al. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 1998, 12(16):2227-2228.
7. Skiest D.J., Vazquez J.A., Anstead G.M., et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007, 44(4):607-614.
8. Ally R., Schurmann D., Kreisel W., et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001, 33(9):1447-1454.
9. Wilcox C.M., Darouiche R.O., Laine L., et al. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 1997, 176(1):227-232.
10. Villanueva A., Arathoon E.G., Gotuzzo E., et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001, 33(9):1529-1535.
11. Villanueva A., Gotuzzo E., Arathoon E.G., et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002, 113(4):294-299.
12. Reed E.C., Wolford J.L., Kopecky K.J., et al. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial. Ann Intern Med 1990, 112(7):505-510.
13. Frobert E., Ooka T., Cortay J.C., et al. Herpes simplex virus thymidine kinase mutations associated with resistance to acyclovir: a site-directed mutagenesis study. Antimicrob Agents Chemother 2005, 49(3):1055-1059.
14. Malvy D., Treilhaud M., Bouee S., et al. A retrospective, case-control study of acyclovir resistance in herpes simplex virus. Clin Infect Dis 2005, 41(3):320-326.
15. Biron K.K. Antiviral drugs for cytomegalovirus diseases. Antiviral Res 2006, 71(2-3):154-163.
16. Blanshard C., Benhamou Y., Dohin E., et al. Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison. J Infect Dis 1995, 172(3):622-628.
17. Raijman I., Siddique I., Ajani J., et al. Palliation of malignant dysphagia and fistulae with coated expandable metal stents: experience with 101 patients. Gastrointest Endosc 1998, 48(2):172-179.
18. Benson A.B., Schrag D., Somerfield M.R., et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004, 22(16):3408-3419.
19. Sargent D.J., Niedzwiecki D., O'Connell M.J., et al. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001, 345(2):144-145. [author reply: 146].
20. Sloan J.A., Goldberg R.M., Sargent D.J., et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 2002, 20(6):1491-1498.
21. Kuebler J.P., Wieand H.S., O'Connell M.J., et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007, 25(16):2198-2204.
22. Perez-Soler R., Chachoua A., Hammond L.A., et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004, 22(16):3238-3247.
23. Strumberg D., Clark J.W., Awada A., et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007, 12(4):426-437.
24. Miller R.C., Martenson J.A., Sargent D.J., et al. Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma. Int J Radiat Oncol Biol Phys 1998, 41(3):593-598.
25. Wadler S., Benson A.B., Engelking C., et al. Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 1998, 16(9):3169-3178.
26. Benson A.B., Ajani J.A., Catalano R.B., et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004, 22(14):2918-2926.
27. Abigerges D., Armand J.P., Chabot G.G., et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994, 86(6):446-449.
28. Kneebone A., Mameghan H., Bolin T., et al. The effect of oral sucralfate on the acute proctitis associated with prostate radiotherapy: a double-blind, randomized trial. Int J Radiat Oncol Biol Phys 2001, 51(3):628-635.
29. Barbounis V., Koumakis G., Vassilomanolakis M., et al. Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Support Care Cancer 2001, 9(4):258-260.
30. Goumas P., Naxakis S., Christopoulou A., et al. Octreotide acetate in the treatment of fluorouracil-induced diarrhea. Oncologist 1998, 3(1):50-53.
31. Rubin J., Ajani J., Schirmer W., et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999, 17(2):600-606.
32. Kelly C.P., Pothoulakis C., LaMont J.T. Clostridium difficile colitis. N Engl J Med 1994, 330(4):257-262.
33. Gorschluter M., Mey U., Strehl J., et al. Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol 2005, 75(1):1-13.
34. Anand A., Glatt A.E. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993, 17(1):109-113.
35. Bartlett J.G. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002, 346(5):334-339.
36. Apisarnthanarak A., Razavi B., Mundy L.M. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002, 35(6):690-696.
37. Tedesco F.J., Gordon D., Fortson W.C. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 1985, 80(11):867-868.
38. Johnson S., Schriever C., Galang M., et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007, 44(6):846-848.
39. Lowy I., Molrine D.C., Leav B.A., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010, 362(3):197-205.
40. Urbach D.R., Rotstein O.D. Typhlitis. Can J Surg 1999, 42(6):415-419.
41. Sloas M.M., Flynn P.M., Kaste S.C., et al. Typhlitis in children with cancer: a 30-year experience. Clin Infect Dis 1993, 17(3):484-490.
42. Kouroussis C., Samonis G., Androulakis N., et al. Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five cases. Am J Clin Oncol 2000, 23(3):309-313.
43. Wade D.S., Nava H.R., Douglass H.O. Neutropenic enterocolitis. Clinical diagnosis and treatment. Cancer 1992, 69(1):17-23.
44. Schwartz J.M., Wolford J.L., Thornquist M.D., et al. Severe gastrointestinal bleeding after hematopoietic cell transplantation, 1987-1997: incidence, causes, and outcome. Am J Gastroenterol 2001, 96(2):385-393.
45. Snover D.C., Weisdorf S.A., Vercellotti G.M., et al. A histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. Hum Pathol 1985, 16(4):387-392.
46. McCaul K.G., Nevill T.J., Barnett M.J., et al. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin. J Hematother Stem Cell Res 2000, 9(3):367-374.
47. Patriarca F., Sperotto A., Damiani D., et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004, 89(11):1352-1359.
48. Carlens S., Ringden O., Remberger M., et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant 1998, 22(8):755-761.
49. Akpek G., Chinratanalab W., Lee L.A., et al. Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study. Biol Blood Marrow Transplant 2003, 9(1):46-51.
50. Shulman H.M., Sharma P., Amos D., et al. A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation. Hepatology 1988, 8(3):463-470.
51. Couriel D., Carpenter P.A., Cutler C., et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006, 12(4):375-396.
52. Babb R.R. Radiation proctitis: a review. Am J Gastroenterol 1996, 91(7):1309-1311.
53. Mayer R., Klemen H., Quehenberger F., et al. Hyperbaric oxygen-an effective tool to treat radiation morbidity in prostate cancer. Radiother Oncol 2001, 61(2):151-156.
54. al-Sabbagh R., Sinicrope F.A., Sellin J.H., et al. Evaluation of short-chain fatty acid enemas: treatment of radiation proctitis. Am J Gastroenterol 1996, 91(9):1814-1816.
55. Fantin A.C., Binek J., Suter W.R., et al. Argon beam coagulation for treatment of symptomatic radiation-induced proctitis. Gastrointest Endosc 1999, 49(4 Pt 1):515-518.
56. Taieb S., Rolachon A., Cenni J.C., et al. Effective use of argon plasma coagulation in the treatment of severe radiation proctitis. Dis Colon Rectum 2001, 44(12):1766-1771.
57. Lucarotti M.E., Mountford R.A., Bartolo D.C. Surgical management of intestinal radiation injury. Dis Colon Rectum 1991, 34(10):865-869.
58. Singhal S., Mehta J., Desikan R., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341(21):1565-1571.
59. Portenoy R.K., Thomas J., Moehl Boatwright M.L., et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage 2008, 35(5):458-468.
60. Liang R., Lau G.K., Kwong Y.L. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999, 17(1):394-398.
61. Aksoy S., Harputluoglu H., Kilickap S., et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007, 48(7):1307-1312.
62. Yeo W., Chan P.K., Zhong S., et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000, 62(3):299-307.
63. Yeo W., Zee B., Zhong S., et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004, 90(7):1306-1311.
64. Yeo W., Chan P.K., Ho W.M., et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004, 22(5):927-934.
65. Keeffe E.B., Dieterich D.T., Han S.H., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006, 4(8):936-962.
66. Kawatani T., Suou T., Tajima F., et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 2001, 67(1):45-50.
67. Lee W.M. Drug-induced hepatotoxicity. N Engl J Med 1995, 333(17):1118-1127.
68. Goldberg J.W., Lidsky M.D. Cyclophosphamide-associated hepatotoxicity. South Med J 1985, 78(2):222-223.
69. Moertel C.G., Fleming T.R., Macdonald J.S., et al. Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol 1993, 11(12):2386-2390.
70. Kemeny N., Daly J., Reichman B., et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987, 107(4):459-465.
71. Berkowitz R.S., Goldstein D.P., Bernstein M.R. Ten year's experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. Gynecol Oncol 1986, 23(1):111-118.
72. Johnson P.J., Dobbs N., Kalayci C., et al. Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters. Br J Cancer 1992, 65(5):751-755.
73. Vauthey J.N., Pawlik T.M., Ribero D., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006, 24(13):2065-2072.
74. Stoneham S., Lennard L., Coen P., et al. Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia. Br J Haematol 2003, 123(1):100-102.
75. Vassal G., Hartmann O., Benhamou E. Busulfan and veno-occlusive disease of the liver. Ann Intern Med 1990, 112(11):881.
76. Hesketh P.J. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008, 358(23):2482-2494.
77. Gordon M.S., Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005, 69(Suppl 3):25-33.
78. Badgwell B.D., Camp E.R., Feig B., et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 2008, 19(3):577-582.
79. Runzi M., Layer P. Drug-associated pancreatitis: facts and fiction. Pancreas 1996, 13(1):100-109.
80. Davila M., Bresalier R.S. Gastrointestinal complications of oncologic therapy. Nat Clin Pract Gastroenterol Hepatol 2008, 5(12):682-696.
81. Beaven A.W., Shea T.C. The effect of palifermin on chemotherapy and radiation therapy-induced mucositis: a review of the current literature. Support Cancer Ther 2007, 4(4):188-197.